Evolving multidisciplinary treatment of squamous cell carcinoma of the head and neck in India✰

Anand, Anil Kumar; Agarwal, Jai Prakash; D’Cruz, Anil; Dattatreya, Palanki Satya; Goswami, Chanchal; Joshi, Amit; Julka, Pramod Kumar; Noronha, Vanita; Prabhash, Kumar; Rao, Rongsheng; Kumar, Rejnish; Toprani, Rajendra; Saxena, Vijay Laxmi

doi:10.1016/j.ctarc.2020.100269

Cited by 4 publications

(4 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinically, the treatment of HNC is multimodality and surgery to remove the tumour, radiation utilising high-energy rays like X-rays, and chemotherapy—either alone or in combination—are some of the treatment options [ 4 , 10 – 12 ]. The organ-preserving approach preferably with definitive concomitant chemoradiation (CRT) is attempted for locoregionally restricted tumour and involves using surgery as a last resort [ 12 – 14 ]. Surgery followed by adjuvant radiation therapy is the other treatment option options [ 4 , 12 , 15 ].…”

Section: Introductionmentioning

confidence: 99%

“…The organ-preserving approach preferably with definitive concomitant chemoradiation (CRT) is attempted for locoregionally restricted tumour and involves using surgery as a last resort [ 12 – 14 ]. Surgery followed by adjuvant radiation therapy is the other treatment option options [ 4 , 12 , 15 ]. The management of HNC is complex, including a number of disciplines, including medicine, pathology, surgery, radiation oncology, radiology, and supportive services, such as physical and occupational therapy, speech and swallowing therapy, and nutrition [ 11 , 16 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Social, Ethical and Treatment Related Problems Faced by Healthcare Workers in the Care of Head and Neck Cancer Patients: A Narrative Review from the Bioethics Consortium from India

Baliga

Lasrado

Krishna

et al. 2023

Indian J Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

Head and neck cancer (HNC) presents a variety of ethical difficulties for an oncologist involved in screening, diagnosis, treatment, and rehabilitation that are challenging to address, especially for those professionals/people who are not trained in medical ethics. The bioethics department has spent the last ten years compiling information and rating the seriousness of numerous niche ethical concerns and their effects on healthcare professionals practising in India. Based on these findings, the current analysis makes an effort to outline the different challenges faced by oncologists when screening, diagnosing, treating, and rehabilitating people affected with HNC, particularly in a traditional nation like India. According to the authors, this is the first overview to address these issues from an Indian viewpoint, and it represents a small effort to document a crucial but unaddressed component of cancer treatment. It is hoped that these endeavours would aid in educating upcoming healthcare professionals on how to effectively handle the difficulties.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Social, Ethical and Treatment Related Problems Faced by Healthcare Workers in the Care of Head and Neck Cancer Patients: A Narrative Review from the Bioethics Consortium from India

Baliga

Lasrado

Krishna

et al. 2023

Indian J Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

show abstract

“…3 Surgery has been the mainstay treatment modality and well-established standard of care for HNC. 4 5 However, surgical procedures are lengthy and result in deformities, often followed by reduced food intake leading to nutritional deficiencies and weight loss. Additionally, a shift in paradigm has been observed for the treatment of locally advanced HNC cases utilizing radiotherapy (RT) and concurrent chemotherapy in adjuvant settting.…”

Section: Introductionmentioning

confidence: 99%

Impact of Sarcopenia on Head and Neck Cancer Treatment: A Review of Literature

Kantamani,

Bavaskar,

Shetty

et al. 2023

Indian J Med Paediatr Oncol

View full text Add to dashboard Cite

The overall outcome of head and neck cancer (HNC) patients undergoing any treatment modality may significantly depend upon their general nutritional condition. Poor nutritional status leading to sarcopenia may be a negative prognostic factor in determining the outcome of HNC patients. PubMed database was searched to identify studies published between 2015 and 2022. All studies reporting the index for sarcopenia as well as its effect on HNC were included. This narrative review was conducted to specifically evaluate the impact of sarcopenia on HNC patients undergoing surgery/ free flap reconstruction/ adjuvant treatment. In oncology, computed tomography assessment of skeletal mass at C3 and L3 is the most suitable index to detect sarcopenia. From the articles yielded, the prevalence rate of sarcopenia ranges from 6 to 70% worldwide. Indian population presents with a significantly higher rate of 31.5% sarcopenia HNC patients. Sarcopenic patients have an increased propensity for surgical site infections, as high as 24.6% owing to the reduced skeletal muscle mass. These patients are also prone to have frequent breaks during radiation treatment of more than 1 week and increased chemotherapy-related toxicities. Further, sarcopenic individuals tend to have higher Ryle's tube dependency of more than 90 days. Sarcopenic patients undergoing surgery have a poor overall survival (OS) and disease-free survival (DFS). In terms of hazards ratio, sarcopenic patients have 1.96 times poor OS and 2.00 times poor DFS when compared to normal individuals who undergo HNC surgery. Sarcopenia is an indispensable part of cancer ailment and it is an independent factor negatively influencing DFS and OS. Thus, nutritional strategy needs to be developed to mitigate sarcopenic effects, especially in the Indian population in preoperative setting.

show abstract

“…It is the most common type of head and neck tumor (up to 90%) ( Rahman et al, 2019 ). Furthermore, its prognosis is poor ( Pi et al, 2017 ) with a general 5-year survival rate of less than 40% and a 5-year survival rate of only 39.1% in patients with metastases ( Anand et al, 2021 ; Muzaffar et al, 2021 ). Previous etiological studies suggested that smoking and alcohol use are common risk factors ( Leemans et al, 2018 ).…”

Section: Introductionmentioning

confidence: 99%

Effects of immune inflammation in head and neck squamous cell carcinoma: Tumor microenvironment, drug resistance, and clinical outcomes

et al. 2022

View full text Add to dashboard Cite

Background: Head and neck squamous cell carcinoma (HNSCC) is a malignant tumor with a very high mortality rate, and a large number of studies have confirmed the correlation between inflammation and malignant tumors and the involvement of inflammation-related regulators in the progression of HNSCC. However, a prognostic model for HNSCC based on genes involved in inflammatory factors has not been established.Methods: First, we downloaded transcriptome data and clinical information from patients with head and neck squamous cell carcinoma from TCGA and GEO (GSE41613) for data analysis, model construction, and differential gene expression analysis, respectively. Genes associated with inflammatory factors were screened from published papers and intersected with differentially expressed genes to identify differentially expressed inflammatory factor-related genes. Subgroups were then typed according to differentially expressed inflammatory factor-related genes. Univariate, LASSO and multivariate Cox regression algorithms were subsequently applied to identify prognostic genes associated with inflammatory factors and to construct prognostic prediction models. The predictive performance of the model was evaluated by Kaplan-Meier survival analysis and receiver operating characteristic curve (ROC). Subsequently, we analyzed differences in immune composition between patients in the high and low risk groups by immune infiltration. The correlation between model genes and drug sensitivity (GSDC and CTRP) was also analyzed based on the GSCALite database. Finally, we examined the expression of prognostic genes in pathological tissues, verifying that these genes can be used to predict prognosis.Results: Using univariate, LASSO, and multivariate cox regression analyses, we developed a prognostic risk model for HNSCC based on 13 genes associated with inflammatory factors (ITGA5, OLR1, CCL5, CXCL8, IL1A, SLC7A2, SCN1B, RGS16, TNFRSF9, PDE4B, NPFFR2, OSM, ROS1). Overall survival (OS) of HNSCC patients in the low-risk group was significantly better than that in the high-risk group in both the training and validation sets. By clustering, we identified three molecular subtypes of HNSCC carcinoma (C1, C2, and C3), with C1 subtype having significantly better OS than C2 and C3 subtypes. ROC analysis suggests that our model has precise predictive power for patients with HNSCC. Enrichment analysis showed that the high-risk and low-risk groups showed strong immune function differences. CIBERSORT immune infiltration score showed that 25 related and differentially expressed inflammatory factor genes were all associated with immune function. As the risk score increases, specific immune function activation decreases in tumor tissue, which is associated with poor prognosis. We also screened for susceptibility between the high-risk and low-risk groups and showed that patients in the high-risk group were more sensitive to talazoparib-1259, camptothecin-1003, vincristine-1818, Azd5991-1720, Teniposide-1809, and Nutlin-3a (-) −1047.Finally, we examined the expression of OLR1, SCN1B, and PDE4B genes in HNSCC pathological tissues and validated that these genes could be used to predict the prognosis of HNSCC.Conclusion: In this experiment, we propose a prognostic model for HNSCC based on inflammation-related factors. It is a non-invasive genomic characterization prediction method that has shown satisfactory and effective performance in predicting patient survival outcomes and treatment response. More interdisciplinary areas combining medicine and electronics will be explored in the future.

show abstract

Evolving multidisciplinary treatment of squamous cell carcinoma of the head and neck in India✰

Cited by 4 publications

References 100 publications

Social, Ethical and Treatment Related Problems Faced by Healthcare Workers in the Care of Head and Neck Cancer Patients: A Narrative Review from the Bioethics Consortium from India

Social, Ethical and Treatment Related Problems Faced by Healthcare Workers in the Care of Head and Neck Cancer Patients: A Narrative Review from the Bioethics Consortium from India

Impact of Sarcopenia on Head and Neck Cancer Treatment: A Review of Literature

Effects of immune inflammation in head and neck squamous cell carcinoma: Tumor microenvironment, drug resistance, and clinical outcomes

Contact Info

Product

Resources

About